1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final An...
1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
More information
Scope and Contents
Contents
Abstract
Background
In the STORM CHASER phase 3 post-exposure prophylaxis study, 300-mg intramuscular (IM) AZD7442 (tixagevimab/cilgavimab) reduced symptomatic COVID-19 by 33.3% vs placebo at primary analysis (P=0.212; median follow-up: 183 days) and was well tolerated. We report final safety data from STORM CHASER.
Methods
In STORM CHA...
Alternative Titles
Full title
1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1093_ofid_ofad500_1190
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1093_ofid_ofad500_1190
Other Identifiers
ISSN
2328-8957
E-ISSN
2328-8957
DOI
10.1093/ofid/ofad500.1190
